RLAY NASDAQ
Relay Therapeutics, Inc.
1W: +6.9%
1M: -17.3%
3M: +57.0%
YTD: +67.0%
1Y: +347.9%
3Y: +36.7%
5Y: -53.2%
$13.53
-0.13 (-0.95%)
Weekly Expected Move ±8.8%
$10
$11
$12
$13
$14
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
0.45
Bullish
4 bullish
1 neutral
1 bearish
Articles (7d)
6
Daily Sentiment (7 Days)
Articles (100)
Is Relay Therapeutics a Buy After Promising Trial Results?
Relay Therapeutics prices $275M public offering of common stock at $12/share
Why Relay Therapeutics Stock Popped on Wednesday
Lowe's, ZTO Express, Viavi Solutions And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Relay Therapeutics Reports Early Success For Investigational Drug In Rare Vascular Disorders
Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies
Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Lags Revenue Estimates
Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates
Earnings Scheduled For May 5, 2026
Ardelyx (ARDX) Reports Q1 Loss, Beats Revenue Estimates
Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026
Near the top of biotech rankings, AbbVie's Q1 beat makes a case for more upside
Starbucks To Rally More Than 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Relay Therapeutics (RLAY) Falls Hard on Profit-Taking From 74% April Jump
Relay Therapeutics (RLAY) Falls Hard on Profit-Taking From 74% April Jump - Yahoo Finance
Relay Therapeutics (NASDAQ: RLAY) 2026 proxy details director, pay and share votes - Stock Titan
A Quick Look at Today's Ratings for Relay Therapeutics(RLAY.US), With a Forecast Between $18 to $22 - Moomoo
RLAY Stock Slides As Traders Eye Support And Cash Runway - StocksToTrade
RLAY Maintained by Goldman Sachs -- Price Target Raised to $22.00 - GuruFocus
RLAY Maintained by Citizens -- Price Target Raised to $19.00 - GuruFocus
Relay Therapeutics Call Puts Zovegalisib Breast Cancer Prospects In Focus - simplywall.st
Relay Therapeutics (RLAY) surges 16.4%: Is this an indication of further gains? - MSN
$RLAY stock is down 11% today. Here's what we see in our data. - Quiver Quantitative
RLAY Maintained by Wells Fargo -- Price Target Raised to $21.00 - GuruFocus
RLAY Maintained by Oppenheimer -- Price Target Raised to $18.00 - GuruFocus
Citizens raises Relay Therapeutics stock price target on triplet data - Investing.com
Relay Therapeutics Unveils Zovegalisib Triplet Data, Signs Pfizer Supply Deal for Phase III Plan
Relay Therapeutics, Inc. (RLAY) Discusses Zovegalisib Triplet Data and First-Line Breast Cancer Strategy - Slideshow - Seeking Alpha
Breast cancer combo posts 44% response in pretreated patients - Stock Titan
Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer
Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer
RLAY SEC Filings - Relay Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Apellis Pharmaceuticals is the most overbought healthcare stock as Q1 earnings roll on
JonesResearch Initiates Coverage of Relay Therapeutics (RLAY) With a Hold Rating
Top and lowest-rated mid-cap stocks heading into earnings
Catinazzo, Relay Therapeutics CFO, sells $257k in RLAY stock - Investing.com
Relay Therapeutics (NASDAQ:RLAY) Hits New 52-Week High on Analyst Upgrade
Healthcare quant check: RLAY and TNGX lead Seeking Alpha’s top picks ahead of Q1 earnings
JPMorgan Chase & Co. Reduces Position in Relay Therapeutics, Inc. $RLAY
Healthcare quant check: RLAY and TNGX lead Seeking Alpha’s top picks ahead of Q1 earnings - Seeking Alpha
Relay Therapeutics (RLAY) Surges 16.4%: Is This an Indication of Further Gains?
Relay Therapeutics (RLAY) Surges 16.4%: Is This an Indication of Further Gains?
SG Americas Securities LLC Acquires 189,004 Shares of Relay Therapeutics, Inc. $RLAY
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Relay Therapeutics (RLAY) Is Up 30.6% After Expanding Zovegalisib Into Vascular Anomalies Data Reveal
Relay Therapeutics (NASDAQ:RLAY) Reaches New 52-Week High – Time to Buy?
Relay Therapeutics (RLAY) Climbs 16% Ahead of Cancer Treatment Update
Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026
Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026
12 Health Care Stocks Moving In Thursday's Intraday Session
Relay Therapeutics (NASDAQ:RLAY) Stock Price Up 6.4% - Here's What Happened - MarketBeat
Assessing Relay Therapeutics (RLAY) Valuation After New ReDiscover Trial Data And FDA Breakthrough Status - simplywall.st
RLAY SEC Filings - Relay Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Relay Therapeutics (RLAY) price target increased by 17.50% to 17.43 - MSN
Vanguard realignment reports 0 Relay Therapeutics shares (RLAY) - Stock Titan
HC Wainwright Issues Positive Forecast for RLAY Earnings
Did Phase 1/2 ReDiscover Data Just Reframe Relay Therapeutics' (RLAY) Late-Stage Breast Cancer Strategy? - simplywall.st
Relay Therapeutics (NASDAQ:RLAY) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Assessing Relay Therapeutics (RLAY) Valuation After New Zovegalisib Breast Cancer Data And Ongoing Phase 3 Trial - Sahm
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet.
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet.
Relay Therapeutics (RLAY) — Perceptive entities report 5.3% stake - Stock Titan
Investors Purchase Large Volume of Relay Therapeutics Call Options (NASDAQ:RLAY)
Relay Therapeutics' Cancer Drug Hits 11.1-Month Progression Free Survival - What Does This Means For Pretreated Breast Cancer Patients?
Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026
Experimental Relay cancer drug combo shows 11.1-month progression-free survival - Stock Titan
Relay Therapeutics (NASDAQ:RLAY) Hits New 52-Week High on Analyst Upgrade
Guggenheim raises Relay Therapeutics price target on VM opportunity - Investing.com
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of “Moderate Buy” from Analysts
Relay Therapeutics (RLAY) Soars 5.4%: Is Further Upside Left in the Stock?
Relay Therapeutics (RLAY) Soars 5.4%: Is Further Upside Left in the Stock?
Relay Therapeutics (NASDAQ:RLAY) Sees Unusually-High Trading Volume - What's Next? - MarketBeat
Relay Therapeutics (RLAY) Soars 5.4%: Is Further Upside Left in the Stock? - Yahoo Finance
Relay Therapeutics: Breakthrough Designation Sets The Stage For A Key Zovegalisib Data Catalyst - Seeking Alpha
Relay Therapeutics (RLAY) Valuation After Breakthrough Therapy Win And Narrower Loss Attracts Fresh Investor Interest
Relay Therapeutics (NASDAQ:RLAY) Hits New 12-Month High After Better-Than-Expected Earnings
Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million
Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million
Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million
Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million - Yahoo Finance
Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million - The Motley Fool
Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Lags Revenue Estimates
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones
Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Lags Revenue Estimates
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones
Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million
Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50%
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29%
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026
Assessing Relay Therapeutics (RLAY) Valuation After FDA Breakthrough Therapy Designation For Zovegalisib
Relay Therapeutics Insider Sells 21,000 Shares for $166,700 After 65% Run
Relay Therapeutics Insider Sells 21,000 Shares for $166,700 After 65% Run
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer